Asian PD-1/VEGF and Bispecific Antibodies
As of November 1, 2026, Drugnews tracks 32 Asian programs in PD-(L)1 bispecific antibodies, including PD-1/VEGF and fusion formats across China, Japan, Korea and Taiwan; the most advanced is ivonescimab from Akeso (Approved).
Assets (32)
| Company | Country | Code | Asset | Mechanism / format | Highest stage | Indication | Partner and terms (upfront / total) | Source |
|---|---|---|---|---|---|---|---|---|
| Akeso | China | AK104 | cadonilimab | PD-1 × CTLA-4 bispecific antibody | Approved | Recurrent/metastatic cervical cancer after platinum chemotherapy; approved scope per originator | — | www.akesobio.com clinicaltrials.gov |
| China | AK112 | ivonescimab | PD-1 × VEGF-A bispecific antibody | Approved | EGFR-mutant locally advanced/metastatic non-squamous NSCLC after EGFR-TKI; with chemotherapy | Summit Therapeutics USD 15m / USD 70m | www.akesobio.com clinicaltrials.gov | |
| China | AK129 | — | PD-1 × LAG-3 bispecific antibody | Phase 2 | Advanced solid tumors | — | www.akesobio.com clinicaltrials.gov | |
| Hengrui Pharmaceuticals | China | SHR-1701 | retlirafusp alfa | PD-L1 × TGF-β antibody-receptor fusion | Approved | PD-L1 CPS≥1 advanced gastric/gastroesophageal junction adenocarcinoma | — | s3.eu-central-1.amazonaws.com clinicaltrials.gov www.sipac.gov.cn |
| Nanjing Leads Biolabs | China | LBL-024 | opamtistomig | PD-L1 × 4-1BB bispecific antibody | BLA filed | Previously treated extrapulmonary neuroendocrine carcinoma | — | rss.globenewswire.com clinicaltrials.gov en.prnasia.com |
| Innovent | China | IBI363 | — | PD-1 × IL-2 receptor (α-biased) antibody-cytokine fusion | Phase 3 | Colorectal Cancer | Takeda (portfolio, unallocated) USD 1100m / — | www.takedaoncology.com clinicaltrials.gov |
| China | IBI322 | — | PD-L1 × CD47 bispecific antibody | Phase 2 | Small Cell Lung Cancer | — | img.innoventbio.com clinicaltrials.gov | |
| China | IBI323 | — | PD-L1 × LAG-3 bispecific antibody | Phase 2 | Non Small Cell Lung Cancer | — | img.innoventbio.com clinicaltrials.gov | |
| China/United States | IBI318 | — | PD-1 × PD-L1 bispecific antibody | Phase 1/2 | Advanced Cutaneous Squamous Cell Carcinoma | — | pmc.ncbi.nlm.nih.gov clinicaltrials.gov | |
| China | IBI315 | — | PD-1 × HER2 bispecific antibody | Phase 1 | Advanced Solid Tumor | — | img.innoventbio.com clinicaltrials.gov | |
| China/United States | IBI319 | — | PD-1 × 4-1BB bispecific antibody | Phase 1 | Advanced Malignant Tumors | — | img.innoventbio.com clinicaltrials.gov | |
| China | IBI321 | — | PD-1 × TIGIT bispecific antibody | Phase 1 | Advanced Solid Tumors | — | img.innoventbio.com clinicaltrials.gov | |
| Alphamab Oncology | China | KN046 | — | PD-L1 × CTLA-4 bispecific antibody | Phase 3 | Advanced Pancreatic Ductal Adenocarcinoma | — | www.alphamabonc.com clinicaltrials.gov |
| China | KN052 | — | PD-L1 × OX40 bispecific antibody | Phase 1 | Advanced Solid Tumor | — | www.alphamabonc.com clinicaltrials.gov | |
| Biotheus (Pumis Biotechnology) | China | PM8002 | pumitamig | PD-L1 × VEGF-A bispecific antibody | Phase 3 | Breast Neoplasms | BioNTech (portfolio, unallocated) USD 55m / USD >1055m | www.prnewswire.com clinicaltrials.gov |
| China | PM1003 | — | PD-L1 × 4-1BB bispecific antibody | Phase 1/2 | Advanced Solid Tumors | — | pmc.ncbi.nlm.nih.gov clinicaltrials.gov | |
| RemeGen | China | RC148 | — | PD-1 × VEGF-A bispecific antibody | Phase 3 | Non-Small Cell Lung Cancer | AbbVie USD 650m / USD 5600m | news.abbvie.com clinicaltrials.gov |
| Sunshine Guojian | China | SSGJ-707 | — | PD-1 × VEGF-A bispecific antibody | Phase 2/3 | Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction , or Esophageal Adenocarcinoma; Metastatic Gastric Cancer; Gastroesophageal Junction Cancer; Esophageal Adenocarcinoma | Pfizer USD 1250m / USD 6050m | www.pfizer.com clinicaltrials.gov |
| China | SSGJ-705 | — | PD-1 × HER2 bispecific antibody | Phase 2 | Locally Advanced (Unresectable) or Metastatic Solid Tumors | — | www.3sbio.com clinicaltrials.gov | |
| China | SSGJ-706 | — | PD-1 × PD-L1 bispecific antibody | Phase 2 | First-line Advanced NSCLC Patients | — | www.3sbio.com clinicaltrials.gov | |
| AP Biosciences | Taiwan | AP505 | — | PD-L1 × VEGF bispecific antibody | Phase 2 | Advanced solid tumors | Tasly (mainland China/Hong Kong/Macau) | www.apbioinc.com clinicaltrials.gov www.globenewswire.com |
| Taiwan | AP203 | — | PD-L1 × CD137 (4-1BB) bispecific antibody | Phase 1/2 | Locally Advanced or Metastatic Solid Tumors; Non Small Cell Lung Cancer (NSCLC); Head and Neck Squamous Cell Carcinoma (HNSCC); Esophageal Squamous Cell Carcinoma (ESCC) | — | www.apbioinc.com clinicaltrials.gov | |
| Huabo Biopharm | China | HB0025 | — | PD-L1 × VEGF-A antibody-receptor fusion | Phase 2 | TNBC | — | pmc.ncbi.nlm.nih.gov clinicaltrials.gov |
| EpimAb Biotherapeutics | China | EMB-02 | — | PD-1 × LAG-3 bispecific antibody | Phase 1/2 | Advanced Solid Tumors | — | pmc.ncbi.nlm.nih.gov clinicaltrials.gov |
| Shanghai Henlius | China | HLX301 | — | PD-L1 × TIGIT bispecific antibody | Phase 1/2 | Locally Advanced or Metastatic Solid Tumors; Non-small Cell Lung Cancer | — | www.henlius.com clinicaltrials.gov |
| HanX Biopharmaceuticals | China | HX009 | — | PD-1 × CD47 antibody-receptor fusion | Phase 1/2 | Relapsed/Refractory Lymphoma | — | www.nature.com clinicaltrials.gov |
| Junshi Biosciences | China/Singapore | JS207 | — | PD-1 × VEGF-A bispecific antibody | Phase 1/2 | Advanced Solid Tumor | — | dotbio.com clinicaltrials.gov |
| LaNova Medicines | China | LM299 | — | PD-1 × VEGF-A bispecific antibody | Phase 1/2 | Ovarian Cancer Recurrent | Merck/MSD (global) | www.merck.com clinicaltrials.gov |
| Sichuan Baili | China | SI-B003 | — | PD-1 × CTLA-4 bispecific antibody | Phase 1/2 | Squamous Cell Carcinoma of Head and Neck | — | clinicaltrials.gov clinicaltrials.gov |
| ABL Bio | South Korea | ABL501 | — | PD-L1 × LAG-3 bispecific antibody | Phase 1 | Advanced Solid Tumor | — | www.ablbio.com clinicaltrials.gov |
| South Korea | ABL503 | ragistomig | PD-L1 × 4-1BB bispecific antibody | Phase 1 | Advanced Solid Tumor | NovaBridge joint-development partnership | www.ablbio.com clinicaltrials.gov | |
| ImmuneOnco | China | IMM2510 | palverafusp alfa | PD-L1 × VEGF antibody-receptor fusion | Phase 1 | Advanced Solid Tumors; HCC | SynBioTx (Instil Bio; later Axion Bio) (portfolio, unallocated) USD 10m / USD 2150m | immuneonco.com clinicaltrials.gov |
Asian outbound licensing (7)
| Date | Licensor | Country | Partner | Asset / portfolio | Event type | Territory | Upfront | Potential total | Terms | Source |
|---|---|---|---|---|---|---|---|---|---|---|
| 2023-10-26 | Biotheus | China | BioNTech | PM8002/BNT327; PM8003 and preclinical multispecific options | LICENSE | Ex-Greater China | USD 55m | USD >1055m | Signed Oct 26; public announcement Nov 6; effective Dec 2. Technology-transfer fee USD10m separately disclosed in Nov 2023 6-K; overlap with milestone ceiling not established, so not added to total. Embedded trispecific options make bundle unallocated. | www.sec.gov |
| 2024-06-03 | Akeso | China | Summit Therapeutics | Ivonescimab territory expansion | LICENSE_AMENDMENT | Latin America; Middle East; Africa | USD 15m | USD 70m | USD15m upfront in SEC filing; USD70m potential total in June 2024 release. USD55m is arithmetic residual of total less upfront; no timing split. Original 2022 USD500m deal excluded. | www.sec.gov |
| 2024-08-01 | ImmuneOnco | China | SynBioTx (Instil Bio; later Axion Bio) | IMM2510 + IMM27M | LICENSE | Ex-Greater China | USD 10m | USD 2150m | USD50m upfront+near-term includes USD10m upfront; near-term residual USD40m. Additional milestones USD2.1bn. 2025 IND milestone is follow-on payment, not a second licence. | www.sec.gov |
| 2024-11-14 | LaNova Medicines | China | Merck/MSD | LM-299 / MK-2010 | LICENSE | Global | USD 588m | USD 3288m | Signed Nov 14; closing Dec 20. USD300m technology-transfer milestone is INCLUDED in USD2.7bn ceiling; do not add twice. | www.merck.com |
| 2025-05-19 | 3SBio / Shenyang Sunshine / Sunshine Guojian | China | Pfizer | SSGJ-707 / PF-08634404 | LICENSE | Global ex-China; China option | USD 1250m | USD 6050m | USD100m equity excluded. Optional China rights fee up to USD150m excluded from base total. Closing July 24 not a second transaction. | www.pfizer.com |
| 2025-10-21 | Innovent | China | Takeda | IBI363 + IBI343; option on IBI3001 | LICENSE | Asset-dependent ex-Greater China; U.S. co-commercialization for IBI363 | USD 1100m | — | Headline USD1.2bn includes USD100m equity, yielding USD1.1bn non-equity upfront. Bundle cannot be allocated to IBI363. Takeda release does not give numeric milestone ceiling; no secondary headline substituted. | www.takedaoncology.com |
| 2026-01-12 | RemeGen | China | AbbVie | RC148 / ABBV-1480 | LICENSE | Ex-Greater China | USD 650m | USD 5600m | Royalties excluded; contingent milestones are not cash received. | news.abbvie.com |
FAQ
How many Asian bispecific programs are tracked?
The November 1, 2026 table contains 32 programs in 18 originator groups, including PD-(L)1 bispecific antibodies and fusion formats.
Which program is the most advanced?
Ivonescimab (AK112) from Akeso is approved in China. Approved is the highest stage in this table, shared by 3 programs; this does not mean approval in every country.
Does this page cover only PD-1/VEGF?
It also covers other PD-(L)1 bispecific antibodies and fusion formats. Origin includes China/Singapore and China/United States co-originated programs. Stage means the highest stage reached, not proof that every trial is active.
Which Taiwanese programs are included?
AP Biosciences has AP505 (PD-L1 × VEGF, Phase 2) and AP203 (PD-L1 × CD137, Phase 1/2) in this table.
How many Asian outbound licensing events are listed?
The table contains 7 cross-border licensing events and amendments. Upfront payments and potential total values are separate; mixed-program amounts remain unallocated.